Brokerages expect TG Therapeutics Inc (NASDAQ:TGTX) to announce ($0.37) earnings per share (EPS) for the current fiscal quarter, Zacks Investment Research reports. Two analysts have made estimates for TG Therapeutics’ earnings. The lowest EPS estimate is ($0.43) and the highest is ($0.30). The business is scheduled to announce its next quarterly earnings results on Tuesday, February 11th.
On average, analysts expect that TG Therapeutics will report full-year earnings of ($1.96) per share for the current fiscal year, with EPS estimates ranging from ($2.19) to ($1.83). For the next year, analysts anticipate that the company will report earnings of ($1.45) per share, with EPS estimates ranging from ($1.98) to ($0.76). Zacks’ earnings per share calculations are an average based on a survey of research analysts that that provide coverage for TG Therapeutics.
TG Therapeutics (NASDAQ:TGTX) last posted its earnings results on Tuesday, November 12th. The biopharmaceutical company reported ($0.69) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.36) by ($0.33). The business had revenue of $0.04 million for the quarter, compared to analysts’ expectations of $0.04 million. TG Therapeutics had a negative net margin of 123,130.93% and a negative return on equity of 2,411.79%.
Large investors have recently added to or reduced their stakes in the business. UBS Asset Management Americas Inc. lifted its stake in shares of TG Therapeutics by 2.5% during the 2nd quarter. UBS Asset Management Americas Inc. now owns 609,374 shares of the biopharmaceutical company’s stock worth $5,271,000 after purchasing an additional 14,975 shares during the period. Swiss National Bank increased its stake in TG Therapeutics by 19.9% in the second quarter. Swiss National Bank now owns 140,500 shares of the biopharmaceutical company’s stock valued at $1,215,000 after purchasing an additional 23,300 shares during the last quarter. JPMorgan Chase & Co. increased its stake in TG Therapeutics by 12.7% in the second quarter. JPMorgan Chase & Co. now owns 258,296 shares of the biopharmaceutical company’s stock valued at $2,061,000 after purchasing an additional 29,098 shares during the last quarter. Bank of New York Mellon Corp increased its stake in TG Therapeutics by 10.5% in the second quarter. Bank of New York Mellon Corp now owns 311,004 shares of the biopharmaceutical company’s stock valued at $2,690,000 after purchasing an additional 29,627 shares during the last quarter. Finally, Artal Group S.A. lifted its position in TG Therapeutics by 12.5% during the second quarter. Artal Group S.A. now owns 900,000 shares of the biopharmaceutical company’s stock worth $7,785,000 after buying an additional 100,000 shares during the period. Institutional investors own 48.63% of the company’s stock.
Shares of NASDAQ TGTX opened at $7.12 on Friday. The firm’s 50-day moving average is $7.22 and its two-hundred day moving average is $6.94. TG Therapeutics has a 12-month low of $3.32 and a 12-month high of $9.38. The company has a quick ratio of 1.00, a current ratio of 1.00 and a debt-to-equity ratio of 2.77.
About TG Therapeutics
TG Therapeutics, Inc, a biopharmaceutical company, engages in developing and delivering medicines for patients with chronic lymphocytic leukemia (CLL), non-Hodgkin's Lymphoma (NHL), and Multiple Sclerosis (MS). It develops a robust B-cell directed research and development platform for identification of key B-cell pathways of interest and rapid clinical testing.
Read More: Profit margin is different from the revenue
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for TG Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TG Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.